Physician profile
John Davis
NPI 1639286560
$3,191.14
in general payments reported to CMS, 2019-2025
29 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $281 · 2021: $302 · 2022: $363 · 2023: $683 · 2024: $663 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.32 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $422.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $237.17 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $216.19 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $214.30 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Merck Sharp & Dohme LLC | $197.56 | 2020-2025 | Gardasil 9, Capvaxive, Vaqta |
| Astellas Pharma US INC | $180.40 | 2022-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $179.32 | 2019-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $142.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.00 | 2019-2024 | |
| Amarin Pharma, INC. | $98.97 | 2020-2021 | |
| Pfizer INC. | $87.14 | 2020-2025 | |
| Almatica Pharma LLC | $59.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $45.44 | 2020 | |
| Inspire Medical Systems, INC. | $44.29 | 2025 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $42.80 | 2023 | |
| Nevro Corp. | $39.90 | 2024 | Senza |
| Ironshore Pharmaceuticals INC. | $37.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.52 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.70 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.86 | 2019 | |
| Boston Scientific Corporation | $18.86 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.90 | 2019 | |
| Eisai INC. | $14.63 | 2021 | |
| Shire North American Group INC | $13.41 | 2019 | |
| Ibsa Pharma INC. | $12.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.